Refining endpoints in brain tumor clinical trials

被引：0
作者：
Christina A. Meyers
Edwin P. Rock
Howard A. Fine
机构：
[1] M.D. Anderson Cancer Center,Department of Neuro
[2] Otsuka Pharmaceutical Development and Commercialization Inc,Oncology
[3] National Cancer Institute,Neuro
来源：
Journal of Neuro-Oncology | 2012年 / 108卷
关键词：
Brain cancer; Clinical trials; Neurocognitive function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.
引用
收藏
页码：227 / 230
页数：3
相关论文
共 39 条
[1]  
Meyers CA(2000)Cognitive function as a predictor of survival in patients with recurrent malignant glioma J Clin Oncol 18 646-650
[2]  
Hess KR(2003)Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression Neuro Oncol 5 89-95
[3]  
Yung WKA(2010)Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 1943-1972
[4]  
Levin VA(1991)Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials J Clin Oncol 9 2225-2232
[5]  
Meyers CA(2006)Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma J Clin Oncol 24 5427-5433
[6]  
Hess KR(2011)Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab Neuro Oncol 13 660-668
[7]  
Wen PY(2006)The role and relevance of neurocognitive assessment in clinical trials of patients with central nervous system tumors J Clin Oncol 24 1305-1309
[8]  
Macdonald DR(2003)The use of the Mini Mental State Examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity J Clin Oncol 21 3557-3558
[9]  
Reardon DA(2004)Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized phase III trial J Clin Oncol 22 157-165
[10]  
O’Shaughnessy JA(2011)Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer Int J Radiat Oncol Biol Phys 81 77-84
1234